Supporting Patients in the Evolving Treatment Landscape of MS: Constance V. Katsafanas, DO

WATCH TIME: 5 minutes | Captions are auto-generated and may contain errors.

"What I tell my patients is something I heard years ago: when you have MS, you have a disease—the disease does not have you. You are still the same person you were before diagnosis. This is just something you have, and we can manage it."

The landscape of multiple sclerosis (MS) diagnosis and management has evolved substantially, driven by advances in neuroimaging, biomarker research, and revised diagnostic criteria that aim to enable earlier, mor precision detection of the disease. For example, recent updates to the McDonald criteria formally incorporate advanced MRI features and cerebrospinal fluid biomarkers to allow diagnosis even before a first clinical attack or significant disability accrues.¹ This evolving understanding underscores the complexity of MS as an immune-mediated condition and highlights ongoing efforts to refine how the disease is defined as well as monitored.

Concurrently, the therapeutic landscape for MS has expanded from early injectable agents to a broad array of disease-modifying therapies that balance efficacy, safety, and patient preferences. Contemporary approaches include oral agents, infusions, and monoclonal antibodies targeting distinct immunological pathways. Evidence even suggests that early initiation of highly effective therapy may offer greater benefit than traditional escalation strategies.² The increasing recognition of biological heterogeneity in MS, including emerging subtypes identified through biomarkers and machine learning, further supports a move toward personalized treatment selection to optimize outcomes.

Expert Constance V. Katsafanas, DO, the director of the Neurology Residency Program at Marcus Neuroscience Institute, a part of Baptist Health South Florida, recently remarked on the progress made in the MS field in terms of managing the disease in an interview with NeurologyLive^®. Throughout the discussion, she emphasized research as a source of hope for understanding underlying autoimmune processes and identifying biomarkers before clinical lesions emerge. Her focus on patient education, the breadth of available treatment options, and the goal of relapse-free living illustrated how clinicians are translating scientific advances into patient-centered care.

REFERENCES
1. Samara A, Ontaneda D. Evolving the Diagnosis of Multiple Sclerosis: A New Landscape in Light of the 2024 McDonald Criteria. Biomedicines. 2025;13(11):2590. Published 2025 Oct 23. doi:10.3390/biomedicines13112590
2. Cree BAC, Mares J, Hartung HP. Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm. Curr Opin Neurol. 2019;32(3):365-377. doi:10.1097/WCO.0000000000000700